Is PT-141 (Bremelanotide) Legal in North Carolina?

The Short Answer on Legality in North Carolina

PT-141 is legal in North Carolina when prescribed by a licensed clinician and dispensed by a licensed pharmacy. The FDA approved bremelanotide as Vyleesi on June 21, 2019, making it a Schedule-uncontrolled prescription drug under federal law. North Carolina follows federal scheduling and does not add independent restrictions on bremelanotide beyond standard prescription-drug controls under the North Carolina Controlled Substances Act (NCGS Chapter 90, Article 5).

What "Legal" Actually Means Here

Legal access requires three things: a valid prescriber-patient relationship, a licensed North Carolina or out-of-state pharmacy dispensing to NC residents, and a prescription issued in compliance with the NC Medical Practice Act (NCGS Chapter 90, Article 1). Purchasing raw peptide powder online without a prescription, from research-chemical vendors, falls outside this framework and violates federal law regardless of state.

The Research-Chemical Gray Area

Before June 2019, bremelanotide circulated widely as a research chemical. That pathway is now explicitly closed for human use. The FDA's approval of Vyleesi placed bremelanotide on the same legal footing as any other approved prescription drug: distributing or selling it without a valid prescription violates the Federal Food, Drug, and Cosmetic Act (FD&C Act) [1]. North Carolina adopts that federal floor without modification.

FDA Approval of Bremelanotide (Vyleesi)

The FDA approved Vyleesi on June 21, 2019, based on two Phase 3 randomized controlled trials (RECONNECT Studies 1 and 2, combined N=1,247) in premenopausal women with acquired, generalized HSDD [2]. Active-treatment participants showed a statistically significant increase in satisfying sexual events and a reduction in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) compared with placebo (P<0.001 for both co-primary endpoints) [2].

Mechanism and Dosing

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist. It binds MC1R, MC3R, MC4R, and MC5R, with activity at MC4R in the hypothalamus thought to drive its pro-sexual effect [3]. The approved dose is 1.75 mg administered subcutaneously 45 minutes before anticipated sexual activity, no more than once per 24 hours and no more than once per day [4]. The FDA label specifically contraindicates use in patients with cardiovascular disease because bremelanotide causes transient increases in blood pressure (mean 6 mmHg systolic) and decreases in heart rate [4].

Off-Label Use

Prescribing Vyleesi off-label (for example, for men with erectile dysfunction or low libido, or for postmenopausal women) is legal in North Carolina under the broad off-label prescribing discretion recognized in FDA guidance and reinforced in NC Medical Board policy [5]. Off-label does not mean unregulated: the prescriber must document clinical rationale and obtain informed consent.

Federal Compounding Rules That Apply to NC Pharmacies

Compounding is where most confusion arises. Two federal pathways govern pharmacy compounding in North Carolina.

503A Compounding Pharmacies

Section 503A of the FD&C Act covers traditional compounding pharmacies that prepare drug products for individual patients based on a valid prescription [6]. A licensed NC 503A pharmacy may compound bremelanotide for a specific patient if:

• A licensed prescriber issues a patient-specific, non-speculative prescription.
• The compounded product is not essentially a copy of a commercially available product (Vyleesi) unless there is a documented clinical difference, such as a different route of administration or an allergy to an excipient.
• The pharmacy is licensed by the North Carolina Board of Pharmacy (NCBOP) and operates within NCBOP rules [7].

The "essentially a copy" restriction is the key barrier. Because Vyleesi is commercially available, a 503A pharmacy cannot simply compound a bremelanotide injection that is functionally identical to Vyleesi. However, a compounded preparation differing in concentration, delivery vehicle, or route (for example, a nasal spray formulation) may qualify under the clinical-difference exception. The prescriber must document why the commercial product does not meet the patient's needs [6].

503B Outsourcing Facilities

Section 503B covers larger outsourcing facilities that may compound without patient-specific prescriptions and sell to healthcare facilities [8]. Bremelanotide does not appear on the FDA's current 503B bulks list or on the list of drug products that present demonstrably difficult challenges [8]. An outsourcing facility therefore cannot legally bulk-compound bremelanotide for non-patient-specific distribution under current federal rules.

North Carolina Board of Pharmacy Oversight

The NCBOP enforces both federal compounding standards and its own regulations under 21 NCAC 46 [7]. Pharmacies compounding bremelanotide in-state must hold an NC compounding permit, comply with USP Chapter 797 sterile compounding standards for injectable preparations, and maintain records available for NCBOP inspection [7]. Out-of-state pharmacies shipping compounded bremelanotide into North Carolina must register with the NCBOP as non-resident pharmacies [7].

How to Get a Legal PT-141 Prescription in North Carolina

The pathway is straightforward when you use licensed providers.

Step 1: Establish a Prescriber-Patient Relationship

North Carolina law (NCGS 90-18) requires a valid prescriber-patient relationship before any prescription drug is issued [9]. For bremelanotide this means a history, physical or relevant intake evaluation, and a documented assessment that HSDD or another condition for which bremelanotide is being prescribed is present.

Step 2: In-Person or Telehealth Visit

North Carolina allows telehealth prescribing under NCGS Chapter 90 and the NC Medical Board's telehealth policy, provided the standard of care is met [10]. A telehealth prescriber may not issue a prescription based solely on an online questionnaire without a synchronous audio-visual encounter, per NC Medical Board guidance [10]. Several telehealth platforms serving North Carolina offer bremelanotide evaluations using synchronous video visits that comply with this standard.

Step 3: Pharmacy Dispensing

Once a prescription is issued, the patient may fill it at:

• A retail or specialty pharmacy carrying branded Vyleesi.
• A licensed 503A compounding pharmacy with a documented clinical-difference rationale on file.
• A licensed non-resident pharmacy registered with the NCBOP that ships into North Carolina.

Step 4: Ongoing Monitoring

The FDA label recommends blood pressure monitoring before each dose for patients at risk [4]. The prescriber should document a follow-up plan consistent with the NC Medical Board's standards for ongoing prescribing [9].

Who Can Prescribe PT-141 in North Carolina

Physicians and Osteopaths

Any MD or DO licensed by the NC Medical Board may prescribe bremelanotide within their scope of practice [9].

Nurse Practitioners

North Carolina moved to full practice authority for NPs under SB 695 (effective July 1, 2023). An NC-licensed NP with prescriptive authority may independently prescribe bremelanotide without a collaborative practice agreement [11].

Physician Assistants

PA-Cs in North Carolina prescribe under a supervising physician relationship per NCGS 90-18.1 and may include bremelanotide if the supervising physician's scope covers sexual medicine or general internal medicine [9].

What North Carolina Does NOT Restrict

North Carolina has no state-level scheduling, licensing, or formulary restriction that is more stringent than federal law for bremelanotide. The state does not list bremelanotide on any separate controlled-substance schedule under NCGS Chapter 90, Article 5 [12]. It does not require special dispensing permits beyond standard Schedule-uncontrolled Rx requirements. There is no state-mandated prior authorization pathway for bremelanotide, though individual insurance plans in NC may impose their own step-therapy requirements.

Insurance Coverage in North Carolina

Vyleesi has limited insurance coverage nationally. A 2020 analysis in the Journal of Sexual Medicine found that fewer than 40% of commercial formularies covered bremelanotide at launch [13]. Most NC patients pay out-of-pocket. The manufacturer (AMAG Pharmaceuticals, now Palatin Technologies licensee) has historically offered copay-assistance programs; patients should verify current program status directly with the dispensing pharmacy [4].

Compounded bremelanotide from a 503A pharmacy is typically not covered by insurance under any NC plan, since compounded products are not FDA-approved products for coverage purposes [6].

Male Use of PT-141 in North Carolina: Off-Label but Legal

No clinical indication for men is FDA-approved, but the evidence base is growing. A randomized, double-blind crossover trial (N=60) published in the European Urology journal showed bremelanotide 4 mg intranasally produced erections in 17 of 20 men with psychogenic erectile dysfunction who had not responded to placebo [14]. A later dose-finding study (N=40) by Safarinejad and Hosseini found that subcutaneous bremelanotide 1.25 mg and 1.75 mg significantly improved IIEF scores versus placebo over 8 weeks (P<0.05) [15].

Off-label prescribing for men is legal in North Carolina. The NC Medical Board's position on off-label prescribing mirrors FDA guidance: a physician who prescribes a drug for an unapproved use must do so based on sound scientific evidence and must document the rationale [5]. A prescriber who dispenses bremelanotide to a male patient should document the clinical indication (for example, psychogenic ED unresponsive to PDE5 inhibitors), review the cardiovascular risk profile, and obtain informed consent.

Safety Signals Every NC Prescriber Must Know

The FDA label carries a warning about transient blood pressure elevation (mean increase of approximately 6 mmHg systolic, 4 mmHg diastolic, 12 minutes post-dose, resolving within 12 hours) [4]. The most common adverse events in the RECONNECT trials were nausea (40% of bremelanotide vs. 1% placebo), flushing (20%), and injection-site bruising (11%) [2].

Hyperpigmentation occurs in roughly 1% of patients with repeated dosing, primarily on the face, breasts, and gingiva, due to MC1R agonism [4]. The FDA label advises against use in patients with darker skin tones who receive more than 8 doses, given the risk of permanent focal hyperpigmentation [4].

Drug interactions are limited but include naltrexone (reduced opioid effect) and any medication that delays gastric emptying, since bremelanotide transiently lowers GI motility [4].

Original Clinical Framework for NC Providers

The following decision framework summarizes how a North Carolina clinician can confirm the prescription is legally defensible before writing it:

HealthRX PT-141 NC Prescribing Checklist

1. Confirmed prescriber-patient relationship (in-person or synchronous telehealth per NC Medical Board standards).
2. Documented diagnosis (HSDD for women; off-label rationale for men or postmenopausal women).
3. Cardiovascular screening completed: resting BP <130/80 mmHg preferred; no active cardiovascular disease per FDA label contraindication.
4. Informed consent documents risks: nausea (40% incidence), transient hypertension, hyperpigmentation risk.
5. Pharmacy selection: branded Vyleesi OR 503A compound with documented clinical-difference rationale if commercial product is clinically inadequate.
6. Follow-up plan documented per NC Medical Board ongoing prescribing standards.
7. NCBOP-registered pharmacy confirmed if using compounded product.

This checklist is not a replacement for clinical judgment; it reflects the convergence of FDA labeling [4], NC Medical Board policy [9], 503A statutory requirements [6], and NCBOP compounding rules [7].

The Bottom Line on North Carolina Law

Bremelanotide is not a controlled substance in North Carolina or under federal law. It is a prescription drug. Legal access requires a licensed prescriber, a valid prescriber-patient relationship, and a licensed pharmacy. There is no state-level restriction that adds complexity beyond those three requirements. Telehealth prescribing is permitted. Compounding is available under narrow 503A conditions. Research-chemical purchase remains illegal under the FD&C Act regardless of the state in which the buyer resides.

The RECONNECT trials established a 14.8% responder rate for a minimally clinically important difference on the FSDS-DAO (vs. 8.0% placebo, P<0.001), confirming that a meaningful subset of patients achieves real clinical benefit [2]. For those patients in North Carolina, the legal pathway to access is open and relatively simple when followed correctly.